

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[CFDA Numbers: 93.581, 93.587, 93.612, 93.340]

Request for Public Comment on the Proposed Adoption of Administration for Native Americans Program Policies and Procedures; Correction

AGENCY: Administration for Native Americans, ACF, HHS.

ACTION: Notice for Public Comment; Correction.

SUMMARY: The Administration for Children and Families, Administration for Native Americans (ANA), published a notice for public comment in the *Federal Register* of December 8, 2015, on the proposed adoption of program policies and procedures concerning FY 2016 Funding Opportunity Announcements (FOA). The document contained incorrect information under “Section D. Changes to Evaluation Criteria for All FOAs (FOA *Section V.1. Criteria*); 45 CFR 75.204” concerning evaluation criteria and point values for the Native Youth Initiative for Leadership, Empowerment, and Development (hereinafter referred to as “Native Youth I-LEAD”) Funding Opportunity Announcement (HHS–2016–ACF–ANA–NC–1167).

DATES: The deadline for receipt of comments is 15 days from publication of this Notice for Public Comment; Correction in the *Federal Register*.

ADDRESSES: Send comments in response to this correction notice via email to Lillian Sparks Robinson, Commissioner, ANA, at ANACommissioner@acf.hhs.gov. Comments will be available for inspection by members of the public at the Administration for Native Americans, 330 C Street SW., Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Carmelia Strickland, Director, Division of Program Operations, ANA, (877) 922–9262.

Correction

In the *Federal Register* of December 8, 2015, in Volume 80, No. 235, on page 76296, in the third column, correct section “D. Changes to Evaluation Criteria for All FOAs (FOA *Section V.1. Criteria*); 45 CFR 75.204” to read:

D. Changes to Evaluation Criteria for All FOAs FOA (*Section V.1. Criteria*), except the Native Youth I-LEAD FOA; 45 CFR 75.204:

1. Changes to Evaluation Criteria Maximum Point Values: In all FY 2016 FOAs, except the Native Youth I-LEAD FOA (HHS–2016–ACF–ANA–NC–1167), ANA proposes to adjust the maximum point values of evaluation criteria to prioritize the elements that are important to project monitoring and project success. ANA intends to add five points to the value for the Approach Criterion for a maximum point value of 35. The point value for the Objective Work Plan (OWP) criterion will be reduced by five points for a maximum point value of 20 points.

ANA proposes to use the following maximum point values for criteria in all FY 2016 FOAs, except the Native Youth I-LEAD FOA:

Evaluation criteria	Maximum point values
Need for Assistance	10 points.
Outcomes Expected	25 points.
Project Approach	35 points.
Objective Work Plan	20 points.
Budget and Budget Justification	10 points.

The remainder of Section D. is correct.

Correction

Section “E. Change to Recipient Reporting Requirements for All FOAs (FOA *Section VI.3.Reporting*

Requirements); 45 CFR 75.342” is changed to:

E. Proposed Evaluation Criteria for the Native Youth I-LEAD (FOA *Section V.1.Criteria*) (HHS–2016–ACF–ANA–NC–1167); 45 CFR 75.204” added:

1. Evaluation Criteria: The evaluation criteria will offer up to five Bonus Points for applications that include letters of support from community-based youth that describe how they were involved in the planning of the proposed project and how they will continue their involvement in the project’s implementation.

ANA proposes to use the following maximum point values for criteria in the Native Youth I-LEAD FOAs:

Evaluation criteria	Maximum point values
Need for Assistance	10 points.
Outcomes Expected	35 points.
Approach	40 points.
Budget and Budget Justification	15 points.
Bonus Points	5 points.

Submission of an OWP form will not be required of Native Youth I-LEAD applicants therefore there will not be an evaluation criterion related to the OWP.

2. In the evaluation of Native Youth I-LEAD applications, ANA intends to include youth ages 18 to 25 as objective reviewers and subject matter experts. As applicable to all objective reviewers, youth reviewers will also be subject to conflict of interest requirements and confidentiality certification.

3. In scoring each section of a Native Youth I-LEAD application, objective reviewers will use the scales in the following table. Each criterion has five reference guides. Reviewers will assign a score within the range between the minimum and maximum possible points for each criterion.

Need for assistance (10 pts)	Outcomes expected (35 pts)	Approach (40 pts)	Budget and budget justification (15 pts)	Bonus (5 pts)	Guidance
0	0	0	0	0	No information provided. No strengths.
1–3	1–5	1–8	1–3	1–2	Limited or incomplete proposal lacking detail.
4–5	5–10	9–16	4–6	2–3	Some incomplete discussion or insufficient detail.
6–8	11–30	17–35	7–10	3–4	Strong overall discussion and detail.
9–10	31–35	36–40	11–15	5	Detailed and compelling proposal. No weaknesses.

Correction

Section F. Relocation of ANA Offices is changed to F. Change to Recipient Reporting Requirements for All FOAs

(FOA *Section VI.3.Reporting Requirements*); 45 CFR 75.342; and a new Section G. is added as “G. Relocation of ANA Offices.” There are

no changes to the content of these sections.

Statutory Authority: Section 814 of the Native American Programs Act of 1974, as amended.

Lillian Sparks Robinson,

Commissioner, Administration for Native Americans.

[FR Doc. 2016-03132 Filed 2-16-16; 8:45 am]

BILLING CODE 4184-34-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]

Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Science Board to the Food and Drug Administration (Science Board).

General Function of the Committee: The Science Board provides advice to the Commissioner of Food and Drugs and other appropriate officials on specific, complex scientific and technical issues important to the FDA and its mission, including emerging issues within the scientific community. Additionally, the Science Board provides advice to the Agency on keeping pace with technical and scientific developments including in regulatory science, input into the Agency's research agenda and on upgrading its scientific and research facilities and training opportunities. It will also provide, where requested, expert review of Agency-sponsored intramural and extramural scientific research programs.

Date and Time: The meeting will be held on March 1, 2016, from 8:30 a.m. until 5 p.m.

Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503, Section A), Silver Spring, MD 20993-0002. For those unable to attend in person, the meeting will also be webcast. The link for the webcast is available at <https://collaboration.fda.gov/scienceboard0316/>. Answers to commonly asked questions including information regarding special

accommodations due to a disability, visitor parking, and transportation may be accessed at: <http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm>.

Contact Person: Rakesh Raghuvanshi, Office of the Chief Scientist, Office of the Commissioner, Food and Drug Administration, Bldg. 1 Rm. 3309, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-4769, rakesh.raghuvanshi@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at <http://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Agenda: The Science Board will hear about and discuss: (1) The role of opioids in pain management; (2) scientific challenges facing FDA in supporting the development of pain medications, including opioids, that have reduced risks of being abused; (3) scientific challenges facing FDA in seeking to understand the real-world use of opioids to treat pain, including the impact of opioids with potentially less risk for abuse; (4) the role that FDA plays as a part of a larger Federal, State, and local response to the challenges of providing appropriate pain treatment while reducing opioid abuse; and (5) postmarket surveillance activities related to opioids. The Science Board will also receive a final report from the Centers of Excellence in Regulatory Science and Innovation Program Evaluation Subcommittee.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before February 23, 2016. Oral presentations from the public will be scheduled between approximately 3:15 and 4:15 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before February 23, 2016. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to February 25, 2016.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Mr. Rakesh Raghuvanshi at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

FDA regrets that it was unable to publish this notice 15 days prior to the March 1, 2016, meeting of the Science Board. Because the Agency believes there is some urgency to bring these issues to public discussion and qualified members of the Science Board were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).